Observational Real-life Study of Cabozantinib in Monotherapy or in Combination With Nivolumab in Advanced Renal Cell Carcinoma (RCC)
NCT ID: NCT04106349
Last Updated: 2025-12-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
150 participants
OBSERVATIONAL
2020-03-03
2027-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1st line
No interventions assigned to this group
2nd line
No interventions assigned to this group
later lines
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients scheduled to receive Cabometyx® in monotherapy or in combination with nivolumabfor advanced or metastatic renal cell carcinoma
* Decision to treat patients with Cabometyx® in monotherapy or in combination with nivolumab has to be taken prior to and independent from participation in the clinical study
* Provision of written informed consent
Exclusion Criteria
* Previous participation in this clinical study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ipsen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ipsen Medical Director
Role: STUDY_DIRECTOR
Ipsen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Onze-Lieve-vrouw Ziekenhuis Aalst
Aalst, , Belgium
Imeldaziekenhuis
Bonheiden, , Belgium
Clinique Saint-Luc Bouge
Bouge, , Belgium
AZ Sint-Jan Brugge
Bruges, , Belgium
AZ Sint-Lucas
Bruges, , Belgium
UZ Brussel
Brussels, , Belgium
Ziekenhuis Oost-Limburg Genk
Genk, , Belgium
Universitair Ziekenhuis Gent
Ghent, , Belgium
Hôpital de Jolimont
La Louvière, , Belgium
CHC MontLegia
Liège, , Belgium
CHR Citadelle Liège
Liège, , Belgium
CHU Liège / Sart-Tilman
Liège, , Belgium
Hôpital Ambroise-Paré Mons
Mons, , Belgium
CHU Charleroi - site André Vésale
Montigny-le-Tilleul, , Belgium
Clinique Saint-Pierre
Ottignies, , Belgium
AZ Delta
Roeselare, , Belgium
AZ Glorieux
Ronse, , Belgium
CHWAPI
Tournai, , Belgium
AZ Turnhout
Turnhout, , Belgium
CHR Verviers
Verviers, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A-BE-60000-047
Identifier Type: -
Identifier Source: org_study_id